Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution

@article{Yoshida2016IncidenceOH,
  title={Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution},
  author={Taichi Yoshida and Daiki Taguchi and Koji Fukuda and Kazuhiro Shimazu and Masahiro Inoue and K Murata and Hiroyuki Shibata},
  journal={International Journal of Clinical Oncology},
  year={2016},
  volume={22},
  pages={244-249}
}
BackgroundRecent approval of molecular-targeted agents has contributed to improving the therapeutic outcomes of advanced cancer patients. However, they result in unusual adverse events that rarely occur with cytotoxic agents, such as hypertension, hypomagnesemia, and an acne-like rash. Although hypophosphatemia can be induced by various agents, some kinds of molecular-targeted agents are known to induce it. In addition, cancer survivors may be at a risk of hypophosphatemia.MethodsOne hundred… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Bone and Mineral Metabolism and Disease

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

[Tumor-induced osteomalacia: a case report].

VIEW 1 EXCERPT

CONCORD Working Group. Global surveillance of cancer survival 1995– 2009: analysis of individual data for 25,676,887 patients from 279 population-based registries

  • C Allemani, HK Weir
  • Lancet
  • 2015
VIEW 1 EXCERPT

Electrolyte disorders associated with cancer.

VIEW 1 EXCERPT

Rickets and osteomalacia (acquired and heritable forms) and skeletal dysplasias

  • MP Whyte, UA Liberman
  • Oxford textbook of endocrinology and diabetes,
  • 2011
VIEW 1 EXCERPT

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.

VIEW 1 EXCERPT